Supernus bags early-stage CNS drug for $15M upfront in renewed epilepsy R&D efforts
A few years into marketing their two epilepsy drugs, the neurology and psychiatry experts at Supernus Pharma are going back to the drawing board with a new asset.
Supernus $SUPN is paying $15 million upfront to acquire Biscayne Neurotherapeutics and their Phase I program, with development and sales milestones totalling $73 million and $95 million respectively. A low single digit royalty would also be due should the drug ever reach the market.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.